GZBL(SZ:002424)2019-04-23 16:00Financial Performance - The company reported a total revenue of 1,411,200,000 RMB for the year 2018, with a cash dividend of 0.80 RMB per 10 shares distributed to all shareholders[8]. - The company's operating revenue for 2018 was ¥3,136,843,231.96, representing a year-over-year increase of 21.03% compared to ¥2,591,816,650.06 in 2017[26]. - The net profit attributable to shareholders for 2018 was ¥563,238,885.60, an increase of 7.05% from ¥526,137,360.96 in 2017[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥555,185,325.81, up 11.56% from ¥497,645,602.87 in 2017[26]. - The basic earnings per share for 2018 was ¥0.40, an increase of 8.11% from ¥0.37 in 2017[26]. - The diluted earnings per share for 2018 was ¥0.39, up 5.41% from ¥0.37 in 2017[26]. - The company achieved a revenue of ¥3,136,843,231.96, representing a year-on-year growth of 21.03%[69]. - The net profit attributable to shareholders was ¥563,238,885.60, reflecting a year-on-year increase of 7.05%[69]. Assets and Liabilities - The company's total assets at the end of 2018 were ¥5,976,300,488.70, a 23.92% increase from ¥4,822,671,249.89 at the end of 2017[26]. - The net assets attributable to shareholders at the end of 2018 were ¥3,870,149,870.84, reflecting a 13.17% increase from ¥3,419,806,985.24 at the end of 2017[26]. - The company's cash and cash equivalents at the end of the reporting period amounted to CNY 545,546,011.66, a decrease of 45.45% compared to the beginning of the year, primarily due to increased investments and reduced net cash flow from operating activities[48]. - Accounts receivable increased to CNY 2,340,455,154.45, up 43.31% from the beginning of the year, attributed to increased sales revenue[51]. - Long-term equity investments rose to CNY 722,495,657.29, a 100% increase, due to capital increase in Yunnan Plant Pharmaceutical Co., Ltd.[51]. - The company reported a net cash flow from operating activities of -¥157,445,351.96, a decrease of 248.57% compared to ¥105,973,362.49 in 2017[26]. Market and Product Development - The company has a comprehensive plan for market expansion and product development, focusing on enhancing its competitive edge in the pharmaceutical sector[8]. - The company has established two traditional Chinese medicine diabetes hospitals in Guiyang and Changsha to expand its integrated TCM project focusing on diabetes treatment[41]. - The company’s main products include Yindan Xinnaotong Soft Capsules and Kesu Ting Syrup, which hold significant market shares in their respective therapeutic areas[41]. - The company has established a comprehensive product structure, with key products like 银丹心脑通软胶囊 showing stable sales growth and significant market share in various therapeutic areas[53]. - The company is developing several innovative drugs, including a new class 1 drug for blood tumors and other projects that will enhance its product portfolio and competitive edge[59]. - The company is actively developing a "Internet + Chronic Disease Medical Service" model in collaboration with Tencent and local health authorities[64]. Research and Development - The company has a strong focus on R&D, with 3 new patents added in 2018 and a total of 58 authorized invention patents by the end of the year[57]. - The company is committed to enhancing its core competitiveness through collaboration with research institutions and universities, fostering innovation and talent development[58]. - The number of R&D personnel increased by 9.27% to 271 in 2018, while R&D investment decreased by 31.74% to ¥50,416,111.58[97]. - The R&D investment accounted for 1.61% of operating income in 2018, down from 2.85% in 2017[97]. Operational Efficiency and Cost Management - The company is focusing on cost control and efficiency improvements to enhance profitability amidst industry challenges[74]. - The company is focused on strengthening internal control management and cost control to enhance operational efficiency[75]. - The company plans to enhance its R&D capabilities by increasing investment in key projects, including new drug development for various therapeutic areas[147]. - The company aims to improve production management systems and ensure compliance with GMP standards to enhance production efficiency and quality[148]. Marketing and Sales - The sales team has expanded significantly, with over 40,000 client relationships established across various sectors[62]. - The company’s star product, Silver Dan Xin Nao Tong Soft Capsule, generated sales revenue of ¥688 million, maintaining stable growth[71]. - The granule product line achieved sales revenue of ¥569 million, marking a growth of 34.07% compared to 2017[71]. - The company plans to optimize its marketing organization and improve the capabilities of its sales team to achieve growth in product sales[144]. Challenges and Risks - The company anticipates risks from pharmaceutical policies and market competition, and will optimize product structure and increase market development efforts[155]. - The company faces potential price reduction risks for drugs and plans to enhance product competitiveness through new product development and quality improvements[156]. - The company acknowledges uncertainties in new drug development and will focus on improving R&D efficiency and project selection[160]. Governance and Compliance - The company is committed to environmental protection and will enhance its energy management system to meet stricter environmental standards[153]. - The company will strengthen its governance structure and internal controls to ensure compliance with regulations and protect investors' rights[149]. - The company has maintained a continuous audit relationship with Tianjian Accounting Firm for 7 years[194]. - The company has ensured compliance with new accounting standards effective from January 1, 2018, with no impact on initial financial data[191]. Shareholder Returns - The company distributed a cash dividend of RMB 0.8 per 10 shares, totaling RMB 112,896,000, which represents 20.04% of the total distributable profit[170][178]. - The total share capital for the dividend distribution is 1,411,200,000 shares, with the record date set for June 13, 2018, and the ex-dividend date on June 14, 2018[172][178]. - The cash dividend policy has been confirmed to comply with the company's articles of association and shareholder resolutions[171]. - The company has maintained a consistent cash dividend policy over the past three years, with no adjustments made during the reporting period[171][178].